We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Image of Ruairi J Mackenzie

Ruairi J Mackenzie

Senior Science Writer

Contact Us

Ruairi started with Technology Networks in January 2018 after completing an undergraduate degree in neuroscience at the University of Edinburgh and a master’s degree in clinical neuroscience from the University of Cambridge. As senior science writer, Ruairi covers a range of scientific news and articles, with a focus on the complexities and curiosities of the brain. Ruairi also looks after search engine optimization (SEO) efforts on Technology Networks and created the site’s podcast, Opinionated Science, in 2020.

Writes for:  


Latest Content
World-First Clinical Trial Explores Safety and Efficacy of DMT for Major Depression
News

World-First Clinical Trial Explores Safety and Efficacy of DMT for Major Depression

The world’s first clinical trial testing the efficacy of the psychedelic compounds N,N-dimethyltryptamine (DMT) has won approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Oxford and AstraZeneca Publish Peer-Reviewed Phase III Data on COVID-19 Vaccine
News

Oxford and AstraZeneca Publish Peer-Reviewed Phase III Data on COVID-19 Vaccine

The University of Oxford and pharmaceutical company AstraZeneca have published a peer-reviewed analysis of Phase III trials of the COVID-19 vaccine ChAdOx1 nCoV-2019 in the Lancet. The publication confirms that ChAdOx1 has an efficacy of 70.4% across two dose regimens, as previously announced.
How Will Genome UK Securely Handle 150 Petabases of Genomic Data?
Industry Insight

How Will Genome UK Securely Handle 150 Petabases of Genomic Data?

Genomic data company PetaGene recently sounded a warning that Genome UK, the UK government’s recently announced genomic healthcare strategy, needs to address important data handling challenges to maintain public trust. To find out more, Technology Networks spoke to PetaGene’s co-founder and chief commercial officer, Vaughan Wittorff, PhD, and co-founder and chief executive officer, Dan Greenfield, PhD.
Old Worm, New Tricks: Old Brains Need Breaks To Maintain Flexibility
News

Old Worm, New Tricks: Old Brains Need Breaks To Maintain Flexibility

Old age takes a toll on our brains. A new study has unraveled how age affects even the most basic of nervous systems: the 302 cells that constitute the “brain” of the nematode worm C. elegans. Findings from this tiny organism may hold lessons for how we treat the aging human brain.
Researchers Trace the Spread of SARS-CoV-2 From Nose to Brain
News

Researchers Trace the Spread of SARS-CoV-2 From Nose to Brain

A study has found that the coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, may be able to access the brain by spreading through the border between our nasal system and neural tissue.
A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer
Industry Insight

A Vaccine for Alzheimer’s Disease? An Interview With AC Immune’s Prof Andrea Pfeifer

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. 2020 has brought mixed news for AC Immune's therapeutics, including promising safety data for their anti-Alzheimer's disease vaccine candidate. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
Opinionated Science Episode 17: I Got COVID-19: Here's What Happened
Podcast

Opinionated Science Episode 17: I Got COVID-19: Here's What Happened

This episode is a COVID-19 podcast with a first-hand focus. Podcast host Ruairi Mackenzie discusses his experience with symptomatic COVID-19. And we also look at the data around COVID-19 risk and age and discuss the emerging problems posed by long COVID.
Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research
Industry Insight

Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research

Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? Technology Networks talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more.
Could DMT-Assisted Therapy Help Treat Mental Health Disorders?
Industry Insight

Could DMT-Assisted Therapy Help Treat Mental Health Disorders?

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.
COVID-19’s Links to Psychiatric Disorders Explored in New Study
News

COVID-19’s Links to Psychiatric Disorders Explored in New Study

A new study has investigated the relationship between COVID-19 and psychiatric illness. The study’s authors say that their findings suggest that a diagnosis of COVID-19 increases the risk of subsequent psychiatric illness.
Advertisement